Effects of Omega-3-6-9 fatty acid supplementation on behavior and sleep in preterm toddlers with autism symptomatology: Secondary analysis of a randomized clinical trial.

Abstract

BACKGROUND

Children born extremely preterm disproportionately experience sequelae of preterm birth compared to those born at later gestational ages, including higher prevalence of autism spectrum disorder (ASD) and associated behaviors. AIM: Explore effects of combined dietary docosahexaenoic acid, eicosapentaenoic acid, gamma-linolenic acid, and oleic acid (omega 3-6-9) on caregiver-reported behavior and sleep in toddlers born at ≤29 weeks' gestation who were exhibiting symptoms commonly seen with ASD.

STUDY DESIGN

90-day randomized (1:1), double blinded, placebo-controlled trial.

SUBJECTS

Thirty-one children aged 18-38 months received omega 3-6-9 (n = 15) or canola oil placebo (n = 16).

OUTCOME MEASURES

Mixed effects regression analyses followed intent to treat and explored treatment effects on measures of caregiver-reported behavior (Child Behavior Checklist 1.5-5, Toddler Behavior Assessment Questionnaire - Short Form, Vineland Adaptive Behavior Scales, 2nd Edition) and sleep (Children's Sleep Habits Questionnaire, Brief Infant Sleep Questionnaire).

RESULTS

Twenty-nine of 31 (94%; n(tx) = 13, n(placebo) = 16) children randomized had data available for at least one outcome measure, 27 (87%; n(tx) = 12, n(placebo) = 15) had complete outcome data. Children randomized to omega 3-6-9 experienced a medium magnitude benefit of supplementation on anxious and depressed behaviors (Δ(Difference) = -1.27, d = -0.58, p = 0.049) and internalizing behaviors (Δ(Difference) = -3.41, d = -0.68, p = 0.05); and a large magnitude benefit on interpersonal relationship adaptive behaviors (Δ(Difference) = 7.50, d = 0.83, p = 0.01), compared to placebo. No effects were observed on other aspects of behavior or sleep.

CONCLUSIONS

Findings provide preliminary support for further exploration of omega 3-6-9 during toddlerhood to improve socioemotional outcomes among children born preterm, especially for those showing early symptoms commonly seen with ASD. Results need to be replicated in a larger sample.

TRIAL REGISTRATION

Registered with ClinicalTrials.gov: NCT01683565.